Disease · HP_0011107
Recurrent aphthous stomatitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Recurrent aphthous stomatitis. Diseases, record HP_0011107. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0011107
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Recurrent aphthous stomatitis
- Open Targets ID
- HP_0011107
- Other names
- Recurrent canker sores, Recurrent oral aphthae
- Highest stage of its drugs
- Phase 3, for 2 of its 13 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs13
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| HYALURONIC ACID | CHEMBL5314376 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets | |
| APREMILAST | CHEMBL514800 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BETAMETHASONE DIPROPIONATE | CHEMBL1200384 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIPHENHYDRAMINE | CHEMBL657 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IBUPROFEN | CHEMBL521 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MAGNESIUM ALUMINUM SILICATE | CHEMBL2109132 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| ZINC SULFATE | CHEMBL1200929 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DICLOFENAC POTASSIUM | CHEMBL1200804 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROPOLIS WAX | CHEMBL4298075 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRIAMCINOLONE ACETONIDE | CHEMBL1504 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 13
See all 13 drugsTargets29
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PDE4A | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 3 | https://conductscience.org/library/genes/5141 | Drugs and targets |
| PDE4B | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 3 | https://conductscience.org/library/genes/5142 | Drugs and targets |
| PDE4C | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 3 | https://conductscience.org/library/genes/5143 | Drugs and targets |
| PDE4D | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 3 | https://conductscience.org/library/genes/5144 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Unknown | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Unknown | https://conductscience.org/library/genes/136 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3269 | Drugs and targets |
1 to 10 of 29
See all 29 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01293968 | Therapeutic Effects of "Ibuprofen, Diphenhydramine and Aluminium MgS" on Recurrent Aphthous Stomatitis | Phase 2 | 37 | 2012-06-20 | Aphthous Stomatitis | DIPHENHYDRAMINE, IBUPROFEN, MAGNESIUM ALUMINUM SILICATE | Its record names the disease | ClinicalTrials.gov |
| NCT04227314 | Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis | Phase 3 | 134 | Recurrent Aphtous Stomatitis | APREMILAST | Its record names the disease | ClinicalTrials.gov | |
| NCT05413096 | Combination of Diclofenac Potassium and Propolis in the Therapy of Oral Aphthosis | Early phase 1 | 100 | Oral Mucositis, ORAS, Oral Infection, Oral Ulcer | DICLOFENAC POTASSIUM, PROPOLIS WAX | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06839313 | Comparison of Hypericum Perforatum, Topical Corticosteroids, and Hyaluronic Acid for Recurrent Aphthous Stomatitis | Not applicable | 75 | Stomatitis, Aphthous | HYALURONIC ACID, ST. JOHN'S WORT, TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT02920658 | Topical "Non-Aromatic Very Rich in Steranes" (NAVS) Naphthalan for the Treatment of Oral Mucosal Diseases | Phase 2 | 57 | Oral Lichen Planus, Recurrent Aphthous Stomatitis | BETAMETHASONE DIPROPIONATE | Its record names the disease | ClinicalTrials.gov | |
| NCT04265001 | Topical Hyaluronic Acid and Recurrent Aphthous Stomatitis. | Phase 3 | 34 | Recurrent Aphthous Stomatitis | HYALURONIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT00315679 | A Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis | Not applicable | 30 | Recurrent Aphthous Stomatitis | PENTOXIFYLLINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06421038 | Efficacy of Thyme Honey in The Management of Oral Aphthous Ulcers | Not applicable | 20 | Aphthous Stomatitis (Major) (Minor), Treatment Compliance | TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01210014 | Systemic Zinc Sulphate in Treatment of Recurrent Aphthous Ulcerations:A Doubleblind, Placebo Controled Study | Phase 2 | 14 | Aphthous Stomatitis | ZINC SULFATE | Its record names the disease | ClinicalTrials.gov | |
| NCT01127724 | Influence of Different Doses of the Vitamin B12 on Recurrent Aphthous Stomatitis | Not applicable | 8 | Recurrent Aphthous Stomatitis | VITAMIN B12 | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Ibuprofen, Diphenhydramine and Aluminium MgS vs Diphenhydramine and Aluminium MgS: serious adverse events | 0 of 17 | 0 of 14 | 31 | NCT01293968 |
Source Trial comparisons
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0011107
GET https://conductscience.org/api/diseases/v1/HP_0011107/targets?page=2